CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Onivyde for Metastatic Pancreatic Cancer (Closed) – Details

Project Number PC0096-000
Brand Name Onivyde
Generic Name Nanoliposomal Irinotecan
Tumour Type Gastrointestinal
Indication Metastatic Pancreatic Cancer
Funding Request For second-line treatment of metastatic adenocarcinoma of the pancreas in combination with 5-fluorouracil (5-FU) and leucovorin in adult patients who have been previously treated with gemcitabine-based therapy
Review Status Cancelled
Pre Noc Submission Yes
NOC Date
Manufacturer Baxalta Canada Corporation
Sponsor Baxalta Canada Corporation
Clarification The submitter notified pCODR that they will not be filing the submission.
Submission Date (Target Date)
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.